Cerebroprotective effects of aminoguanidine in a rodent model of stroke

Stroke

Volumn 27, Issue 8, 1996, Pages 1393-1398

  Cockroft, Kevin M ^a   Meistrell III, Malcolm ^a   Zimmerman, Gary A ^a,c   Risucci, Donald ^b   Bloom, Ona ^a   Cerami, Anthony ^a   Tracey, Kevin J ^a,b,c  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

cerebral ischemia; glycation end products, advanced; neuroprotection; polyamines; rats

Indexed keywords

AMINOGUANIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PH; ARTICLE; BRAIN PROTECTION; CARBON DIOXIDE TENSION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; STROKE;

EID: 0029794989     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.8.1393     Document Type: Article

References (75)

1. Siesjö BK. Pathophysiology and treatment of focal cerebral ischemia, I: pathophysiology. J Neurosurg. 1992;77:169-184.
2. Siesjö BK. Pathophysiology and treatment of focal cerebral ischemia, II: mechanisms of damage and treatment. J Neurosurg. 1992; 77:337-354.
3. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613-622.
4. Montague PR, Gancayco CD, Winn MJ, Marchase RB, Friedlander JJ. Role of NO production in NMDR receptor-mediated neurotransmitter release in cerebral cortex. Science. 1994;263:973-976.
5. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HSV, Sucher NJ, Loscalzo J, Singel DJ, Stamler JS. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 1993;364:626-632.
6. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA. 1991;88:6368-6371.
7. Zhang J, Dawson V, Dawson T, Snyder S. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science. 1994;263: 687-690.
8. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol. 1988;24:543-551.
9. Smith SE, Meldrum BS. Cerebroprotective effects of lamotrigine after focal cerebral ischemia in rats. Stroke. 1995;26:117-122.
10. Martin D, Chinookoswong N, Miller G. The interleukin-1 receptor antagonist (rhIL-1a) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp Neurol. 1994;130:362-367.
11. Liu T, Clark RK, McDonnell PC, Young PR, Whie RF, Barone FC, Feuerstein GZ. Tumor necrosis factor-α expression in ischemic neurons. Stroke. 1994;25:1481-1488.
12. Rothwell NJ, Relton JK. Involvement of interleukin-1 and lipocortin-1 in ischaemic brain damage. Cerebrovasc Brain Metab Rev. 1993; 5:178-198.
13. Wang X, Vue TL, White RF, Barone FC, Feuerstein GZ. Transforming growth factor-β1 exhibits delayed gene expression following focal cerebral ischemia. Brain Res Bull. 1995;36:607-609.
14. Buttini M, Sauter A, Boddeke HW. Induction of interleukin-1 beta mRNA after focal cerebral ischemia in the rat. Brain Res Mol Brain Res. 1994;23:126-134.
15. Wang X, Yue TL, Barone FC, White RF, Gagnon RC, Feuerstein GZ. Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs follows early response gene expression in transient focal ischemia. Mol Chem Neuropathol. 1995;23:103-114.
16. Muszynski CA, Robertson CS, Goodman JC, Henley CM. DFMO reduces cortical infarct volume after middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab. 1993;13:1033-1037.
17. Kindy MS, Hu Y, Dempsey RJ. Blockade of ornithine decarboxylase enzyme protects against ischemic brain damage. J Cereb Blood Flow Metab. 1994;14:1040-1045.
18. Sauer D, Martin P, Allegrini PR, Bernasconi R, Amacker H, Fagg GE. Differing effects of α-difluoromethylornithine and CGP 40116 on polyamine levels and infarct volume in a rat model of focal cerebral ischaemia. Neurosci Lett. 1992;141:131-135.
19. Trimarchi GR, De Luca R, Arcadi FA, Imperatore C, Ruggeri P, Costa G. Effects of fructose-1,6-bisphosphate on brain polyamine biosynthesis in a rat model of transient cerebral ischemia. Life Sci. 1994;54:1195-1204.
20. Gilad GM, Gilad VH, Wyatt RJ. Accumulation of exogenous polyamines in gerbil brain after ischemia. Mol Chem Neuropathol. 1993; 18:197-210.
21. Paschen W. Polyamine metabolism in reversible cerebral ischemia. Cerebrovasc Brain Metab Rev. 1992;4:59-88.
22. Paschen W, Hallmayer J, Rohn G. Relationship between putrescine content and density of ischemic cell damage in the brain of Mongolian gerbils: effect of nimodipine and barbiturate. Acta Neuropathol (Berl). 1988;76:388-394.
23. Zimmerman GA, Meistrell M III, Bloom O, Cockroft KM, Bianchi M, Risucci D, Broome J, Farmer P, Cerami A, Vlassara H, Tracey KJ. Neurotoxicity of advanced glycation endproducts (AGEs) during focal stroke, and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748.
24. Zimmerman GA, Bloom O, Meistrell M, Ford D, Bianchi M, Tracey KJ. Aminoguanidine attenuates focal cerebral ischemia. Surg Forum. 1994;45:600-603.
25. Foote EF, Look ZM, Giles P, Keane WF, Halstenon CE. The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis. Am J Kidney Dis. 1995;25:420-425.
26. Itakura M, Yoshikawa H, Bannai C, Kato M, Kunika K, Kawakami Y, Yamaoka T, Yamashita K. Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats. Life Sci. 1991;49:889-897.
27. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes. 1991;40:1328-1334.
28. Edelstein D, Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia. 1992;35:96-97.
29. Hammes HP, Martin S. Federlin K, Geisen K, Brownlee M. Aminoguanidine inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A. 1991;88:11555-11558.
30. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes. 1992;41:47-52.
31. Wolff DJ, Lubeskie A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch Biochem Biophys. 1995;316:290-301.
32. Griffiths MJD, Messern M, MacAllister RJ, Evans TW. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol. 1993;110:963-968.
33. Brunton VG, Grant MH, Wallace HM. Spermine toxicity in BHK-21/C13 cells in the presence of bovine serum: the effect of aminoguanidine. Toxic In Vitro. 1994;8:337-341.
34. Duverger D, MacKenzie ET. The quantification of cerebral infarction following focal ischemia in the rat: influence of strain, arterial pressure, blood glucose concentration, and age. J Cereb Blood Flow Metab. 1988;8:449-461.
35. Busto R, Dietrich WD, Globus MYT, Valdes I. Small differences in intraischemic brain temperature critically determine the extent of neuronal injury. J Cereb Blood Flow Metab. 1987;7:729-738.
36. Busto R, Dietrich WD, Globus MYT, Ginsberg MD. The importance of brain temperature in cerebral ischemic injury. Stroke. 1989;20: 1113-1114.
37. Welsh FA, Sims RE, McKee AE. Effect of glucose on recovery of energy metabolism following hypoxia-oligemia on mouse brain: dose-dependence and carbohydrate specificity. J Cereb Blood Flow Metab. 1983;3:486-492.
38. Brint S, Jacewicz M, Kiessling M, Tanabe J, Pulsinelli W. Focal brain ischemia in the rat: methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. J Cereb Blood Flow Metab. 1988;8:474-485.
39. Pulsinelli WA, Waldman S, Rawlinson D, Plum F. Moderate hyperglycemia augments ischemic brain damage: a neuropathologic study in the rat. Neurology. 1982;32:1239-1246.
40. Tu YK, Heros RC, Candia G, Hyodo A, Lagree K, Callahan R, Zervas NT, Karacostas D. Isovolemic hemodilution in experimental focal cerebral ischemia, I: effects on hemodynamics, hemorheology, and intracranial pressure. J Neurosurg. 1988;69:72-81.
41. Wiebers DO, Adams HP, Whisnant JP. Animal models of stroke: are they relevant to human disease? Stroke. 1990;21:1-3.
42. Sharkey J, Butcher SP. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature. 1994;371:336-339.
43. Garcia JH. Experimental ischemic stroke: a review. Stroke. 1984; 15:5-14.
44. Ginsberg MD, Busto R. Rodent models of cerebral ischemia. Stroke. 1989;20:1627-1642.
45. Jacewicz M, Brint S, Tanabe J, Pulsinelli WA. Continuous nimodipine treatment attenuates cortical infarction in rats subjected to 24 hours of focal cerebral ischemia. J Cereb Blood Flow Metab. 1990; 10:89-96.
46. Chen ST, Hsu CY, Hogan EL, Maricq H, Balentine JD. A model of focal ischemic stroke in the rat: reproducible extensive cortical infarction. Stroke. 1986;17:738-743.
47. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 1994;70:138-151.
48. Bucala R, Vlassara H, Cerami A. Advanced glycosylation end-products in post-translational modification of proteins. In: Harding JJ, Crabbe JJC, eds. Post-translational Modification of Protein. Boca Raton, Fla: CRC Press; 1992:53-79.
49. Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest. 1992; 90:439-446.
50. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science. 1988;240:1546-1548.
51. Yan SD, Schmidt AM, Anderson GM, Zhung J, Brett J, Zou YS, Pinsky D, Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biochem. 1994;269:9889-9897.
52. Schmidt AM, Mora R, Cao R, Yan SD, Brett J, Ramakrishnan R, Tsang TC, Simionescu M, Stern D. Endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. Biochemistry. 1994;260:9882-9888.
53. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Costache G, Simionescu N, Simionescu M, Stern D. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA. 1994;91:8807-8811.
54. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Endogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A. 1992;89:12043-12047.
55. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycosylation endproducts upregulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A. 1994;91:9436-9440.
56. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycosylation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A. 1994;91: 11704-11708.
57. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A. 1990;87:9010-9014.
58. Colletti LM, Remick DG, Bunch GD, Kunkel SL, Stricter RM, Campbell DA Jr. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest. 1990;85:1936-1943.
59. Kunkel SL, Stricter RM, Chensue SW, Campbell DA, Remick DG. The role of TNF in diverse pathologic processes. Biotherapy. 1991; 3:135-141.
60. Patt A, Harken AH, Burton LK, Rodell TC, Piermattei D, Schorr WJ, Parker NB, Berger EM, Hoeresh IR, Terada LS, Linas SL, Cheronis JC, Repine JE. Xanthine oxidase-derived hydrogen peroxide contributes to ischemia reperfusion-induced edema in gerbil brains. J Clin Invest. 1988;81:1556-1562.
61. Oliver CN, Starke-Reed PE, Stadtman ER, Liu GJ, Carney JM, Floyd RA. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc Natl Acad Sci U S A. 1990; 87:5144-5147.
62. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990;87:1620-1624.
63. Ghezzi P. TNF and the liver. In: Beutler B, ed. Tumor Necrosis Factor: The Molecules and Their Emerging Role in Medicine. New York, NY: Raven Press Publishers; 1992:87-96.
64. Camarata PJ, Heros RC, Latchaw RE. 'Brain attack': the rationale for treating stroke as a medical emergency. Neurosurgery. 1994;34:144-158.
65. Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci. 1993;13:2651-2661.
66. O'Dell TJ, Huang PL, Dawson TM, Dinerman JL, Snyder SH, Kandel ER, Fishman MC. Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOS. Science. 1994;265:542-545.
67. Iadecola C, Xu X, Xhang F, Casey R, Ross ME. Expression of inducible nitric oxide synthase contributes to brain damage in focal cerebral ischemia. Soc Neurosci Abstr. 1994;20:1479. Abstract.
68. Iadecola C, Zhang F, Xu X. Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol. 1995; 268:R286-R292.
69. Paschen W, Schmidt-Kastner R, Djuricic B, Meese C, Linn F, Hossmann KA. Polyamine changes in reversible cerebral ischemia. J Neurochem. 1987;49:35-37.
70. Gotti B, Duverger D, Bertin J, Carter C, Dupont R, Frost J, Gaudilliere B, MacKenzie ET, Rousseau J, Scatton B, Wick A. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents, I: evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther. 1988;247:1211-1221.
71. Carter C, Benavides J, Legendre P, Vincent JD, Noel F, Thuret F, Lloyd KG, Arbilla S, Zivkovic B, MacKenzie ET, Scatton B, Langer SZ. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents, II: evidence for N-methyl-D-aspartate receptor antagonist properties. J Pharmacol Exp Ther. 1988;247:1222-1232.
72. Dempsey RJ, Roy MW, Meyer K, Tain HH, Olson JW. Polyamine and prostaglandin markers in focal cerebral ischemia. Neurosurgery. 1985;17:635-640.
73. Traynelis SF, Hartley M, Heinemann SF. Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science. 1995;268:873-876.
74. Cockroft KM, Meistrell M III, Cerami A, Tracey KJ. Neurotoxicity of polyamines and neuroprotective effects of aminoguanidine. Surg Forum. 1995;46:578-580.
75. Morgan DML. Polyamine oxidases and oxidized polyamines. In: Bachrach U, Heimer YM, eds. The Physiology of Polyamines. Boca Raton, Fla: CRC Press; 1989:203-229.